Department of Pharmacy, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Oncology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
J Int Med Res. 2020 Dec;48(12):300060520974854. doi: 10.1177/0300060520974854.
Hand-foot syndrome (HFS) is a skin toxicity that occurs in areas of compressed skin. HFS manifests mainly in insensitive palms and the soles of the feet or in erythematous areas on the extremities caused by chemotherapy, which may be related to the dosage. This paper reports a case of HFS caused by liposomal doxorubicin. A 64-year-old Asian woman presented with severe erythema, ulceration, pruritus, and edema-related pain in her back, hands, and feet after receiving four cycles of liposomal doxorubicin. Clinicians and a pharmacist analyzed and evaluated the patient's adverse reactions. After symptomatic treatment and patient education, her HFS symptoms were significantly relieved. The purpose of this study was to raise clinical awareness regarding adverse events following liposomal doxorubicin injection, and to provide new ideas for the clinical treatment of these adverse events.
手足综合征(HFS)是一种发生于受压皮肤部位的皮肤毒性反应。HFS 主要表现为手掌和足底感觉迟钝,或因化疗引起的四肢红斑,这可能与剂量有关。本文报道了一例由脂质体多柔比星引起的 HFS。一位 64 岁的亚洲女性在接受了四周期的脂质体多柔比星治疗后,出现背部、手部和足部严重的红斑、溃疡、瘙痒和与水肿相关的疼痛。临床医生和药剂师对患者的不良反应进行了分析和评估。经过对症治疗和患者教育,她的 HFS 症状明显缓解。本研究旨在提高对脂质体多柔比星注射后不良事件的临床认识,并为这些不良事件的临床治疗提供新思路。